The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that ravulizumab not be considered for reimbursement unless cost effectiveness can be improved relative to comparator treatments*.
The NCPE recommends that vericiguat not be considered for reimbursement*.
The NCPE recommends that ravulizumab (Ultomiris®), for the treatment of adult patients with PNH, be considered for reimbursement provided certain conditions are met.*
The NCPE recommends that andexanet alfa (Ondexxya®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
Following assessment of the company submission, the NCPE recommend that enzalutamide (Xtandi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*
The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.
Version 2.1 of the Rapid Review Submission templates includes a requirement to submit the NCPE Budget Impact Model Template for all Rapid Review submissions. Version 2.1 of this template was published on 07 April 2022 and replaces version 2.0. Submissions using the old template (version 2.0) will be accepted until 12 May 2022.
The NCPE recommends that risdiplam not be considered for reimbursement until cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that inclisiran (Leqvio®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.